| 26/06/2020 |
Publication of Disciplinary Procedures and Enforcement Guidance Materials
• Disciplinary Procedures – Listing Committee (for disciplinary actions commenced on or after 26 June 2020)
• Disciplinary Procedures – Listing Review Committee
• Statement on Settlement of Disciplinary Matters involving Listing Rule Breaches
|
Disciplinary and Enforcement > Disciplinary Procedures & Enforcement Guidance Materials
|
| 24/06/2020 |
Publication of revised Guidance Letter
• GL51-13
|
Interpretation and Guidance > Guidance Letters |
| 08/06/2020 |
Publication of Application Form for Exemption for Directors or Executives of Hong Kong-listed Companies Included in Hang Seng Index, Hang Seng China Enterprises Index or Hang Seng Composite LargeCap, MidCap or SmallCap Index |
Other Resources > Listed Issuer |
| 05/06/2020 |
Publication of Listing Decisions
• To provide guidance on why the Exchange rejected certain listing applications (LD126-2020)
• To provide guidance on why the Exchange returned certain listing applications (LD127-2020)
|
Interpretation and Guidance > Listing Decisions |
| 29/05/2020 |
Regulatory Presentation : New Enhancements to the Biotech Chapter |
Other Resources > New Applicant |
| 22/05/2020 |
Publication of Application Form for Exemption of Directors of Hong Kong-listed Companies or Listing Applicants on Duty Travel to Hong Kong under Compulsory Quarantine of Certain Persons Arriving at Hong Kong Regulation |
Other Resources > Listed Issuer |
| 29/04/2020 |
Publication of Guidance Materials for Biotech Companies
• GL107-20/ GL92-18/ GL86-16/ GL85-16
• FAQ No. 030-2018 to 044-2018
|
Interpretation and Guidance |
| 24/04/2020 |
Publication of the Exchange’s Listed Issuer Regulation Newsletter |
Other Resources > Listed Issuers > Listed Issuer Regulation Newsletter |
| 17/04/2020 |
Publication of Listing Decisions
• Whether the Remaining Group could meet the minimum market capitalisation requirement under Rule 8.09(2) (LD124-2020)
• Whether the Remaining Group could meet the minimum market capitalisation requirement under Rule 8.09(2) (LD125-2020)
|
Interpretation and Guidance > Listing Decisions |
| 17/04/2020 |
Publication of Frequently Asked Questions
• FAQ No. 071-2020
|
Interpretation and Guidance > Frequently Asked Questions |
| 17/04/2020 |
Update of Frequently Asked Questions
• FAQ No. 045-2018 to 052-2018 (Added No. 045A-2018)
|
Interpretation and Guidance > Frequently Asked Questions |
| 01/04/2020 |
Joint Statement in relation to General Meetings in light of the Prevention and Control of Disease (Prohibition on Group Gathering) Regulation |
Other Resources > Listed Issuer |
| 16/03/2020 |
Publication of Further Guidance on the Joint Statement in relation to Results Announcements in light of the COVID-19 Pandemic |
Other Resources > Listed Issuer > Joint Statement in relation to Results Announcements in light of Travel Restrictions related to the Severe Respiratory Disease associated with a Novel Infectious Agent and Frequently Asked Questions |
| 13/03/2020 |
Publication of the Exchange’s Biannual Enforcement Newsletter |
Disciplinary & Enforcement > Enforcement Newsletter |
| 06/03/2020 |
E-training and guidance materials on ESG reporting |
Other Resources > Letters to Issuers |
| 28/02/2020 |
Publication of Guidance Materials on ESG reporting:
• FAQ Series 18
|
Interpretation and Guidance |
| 28/02/2020 |
Publication of revised Guidance Letters and FAQs as a result of Streamlining Guidance Materials Relating to Listing Matters:
• GL36-12/ GL52-13/ GL89-16
• FAQ No. 008-2017 to 022-2017/ FAQ Series 1/ FAQ Series 5/ FAQ Series 8/ FAQ Series 20/ FAQ Series 24/ FAQ Series 26/ FAQ Series 31
|
Interpretation and Guidance |
| 28/02/2020 |
Publication of frequently asked questions on the Joint Statement in relation to Results Announcements in light of Travel Restrictions related to the Severe Respiratory Disease associated with a Novel Infectious Agent
|
Other Resources > Listed Issuer |
| 04/02/2020 |
Publication of Joint Statement in relation to Results Announcements in light of Travel Restrictions related to the Severe Respiratory Disease associated with a Novel Infectious Agent |
Other Resources > Listed Issuer |
| 31/01/2020 |
Publication of Consultation Paper on Corporate WVR Beneficiaries |
Other Resources > Letters to Issuers |
| 31/01/2020 |
Publication of Review of Issuers’ Annual Report Disclosure – Report 2019 |
Other Resources > Letters to Issuers |
| 31/01/2020 |
Review of Issuers’ Annual Report Disclosure – Report 2019 |
Other Resources > Listed Issuers > Exchange’s Review of Issuer’s Annual Disclosure > Review of Issuers’ Annual Report Disclosure |
| 18/12/2019 |
Publication of ESG Guide Consultation Conclusions and Review of Issuers’ ESG Practice Disclosure |
Other Resources > Letters to Issuers |
| 06/12/2019 |
Withdrawal of Listing Decision
• LD67-2013
|
Interpretation and Guidance > Listing Decisions |
| 06/12/2019 |
Publication of Consultation Paper on Review of Chapter 37 – Debt Issues to Professional Investors Only |
Other Resources > Letters to Issuers |
| 22/11/2019 |
Publication of the Exchange’s Listed Issuer Regulation Newsletter |
Other Resources> Listed Issuers> Listed Issuer Regulation Newsletter |
| 08/11/2019 |
Question on amendments to articles of association |
Interpretation and Guidance > Frequently Asked Questions |
